UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers

Cancer discovery, 2020-08, Vol.10 (8), p.1121-1128

2020

Volltextzugriff (PDF)

Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices

Modern pathology, 2019-08, Vol.32 (8), p.1106-1122

2019

Volltextzugriff (PDF)

New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab

Lung cancer (Auckland), 2017-01, Vol.8, p.67-78

2017

Volltextzugriff (PDF)

Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Clinical cancer research, 2023-04, Vol.29 (8), p.1423-1428

2023

Volltextzugriff (PDF)

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study

Journal for immunotherapy of cancer, 2023-07, Vol.11 (7), p.e006994

2023

Volltextzugriff (PDF)

Optimizing Tissue Use: A Step-wise Approach to Diagnosing Squamous Cell Lung Carcinoma on Small Biopsies

Clinical pathology (Thousand Oaks, Ventura County, Calif.), 2020, Vol.13, p.2632010X20921873-2632010X20921873

2020

Volltextzugriff (PDF)

Evaluating of HPV–DNA ISH as an adjunct to p16 testing in oropharyngeal cancer

Future science OA, 2020-10, Vol.6 (9), p.FSO606-FSO606

2020

Volltextzugriff (PDF)

Pilot Study of Dacomitinib for Patients With Metastatic EGFR -Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib

JCO precision oncology, 2021, Vol.5 (5), p.695-700

2021

Volltextzugriff (PDF)

Optimizing adjuvant therapy in EGFR -mutated non-small cell lung cancer

Annals of translational medicine, 2020-12, Vol.8 (23), p.1613-1613

2020

Volltextzugriff (PDF)

Tu1913 CHRONIC IMMUNE-RELATED COLITIS IS COMMON AFTER PD-(L)1 TREATMENT AND MAY BE MITIGATED THROUGH EARLY USE OF BIOLOGIC THERAPY

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-1467-S-1468

2024

Volltextzugriff (PDF)

Potential biomarkers for predicting outcomes in CABG cardiothoracic surgeries

Journal of cardiothoracic surgery, 2013-07, Vol.8 (1), p.176-176, Article 176

2013

Volltextzugriff (PDF)

COVID-19 in patients with lung cancer

Annals of oncology, 2020-10, Vol.31 (10), p.1386-1396

2020

Volltextzugriff (PDF)

Tu1914 OFFICE-BASED FLEXIBLE SIGMOIDOSCOPY ALLOWS RAPID ASSESSMENT AND MANAGEMENT OF SUSPECTED IMMUNE CHECKPOINT INHIBITOR-RELATED COLITIS

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-1468-S-1468

2024

Volltextzugriff (PDF)

Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study

The Lancet (British edition), 2024-01, Vol.403 (10422), p.171-182

2024

Volltextzugriff (PDF)

Corrigendum to “Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer” [Lung Cancer 195 (2024) 107919]

Lung cancer (Amsterdam, Netherlands), 2024-11, Vol.197, p.108000, Article 108000

2024

Volltextzugriff (PDF)

Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline

Journal of clinical oncology, 2023-12, Vol.41 (35), p.5448-5472

2023

Volltextzugriff (PDF)

Optimizing clinical research in a regional cancer center network: A survey-based approach

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e13560-e13560

2024

Volltextzugriff (PDF)

Therapeutic Effects of Repurposed Therapies in Non‐Small Cell Lung Cancer: What Is Old Is New Again

The oncologist (Dayton, Ohio), 2015-08, Vol.20 (8), p.934-945

2015

Volltextzugriff (PDF)

The utilization of pre-treatment neutrophil to lymphocyte ratio as a predictive marker for response to nivolumab therapy in non small cell lung cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e20634-e20634

2017

Volltextzugriff (PDF)

Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2024-09, Vol.195, p.107919, Article 107919

2024

Volltextzugriff (PDF)

Predictive value of baseline clinicopathological factors in non-small cell lung cancer (NSCLC) patients on checkpoint inhibitors (CPI)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14119-e14119

2019

Volltextzugriff (PDF)

A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer

Clinical cancer research, 2024-09, Vol.30 (17), p.3697-3703

2024

Volltextzugriff (PDF)

Outcomes of single-agent PD-(L)-1 versus combination with chemotherapy in patients with PD-L1-high (≥ 50%) lung cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9052-9052

2022

Volltextzugriff (PDF)

A comparison of three clinical factors as predictive markers for response to immunotherapy in non-small cell lung cancer

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e21158-e21158

2018

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(49)

Sprache

Englisch
(49)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Oncology
(21)
Humans
(16)
Lung Cancer
(9)
Lung Neoplasms - Drug Therapy
(8)
Chemotherapy
(6)
Female
(6)
Metastasis
(6)
Cancer Therapies
(5)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(5)
Medical Prognosis
(5)
Middle Aged
(5)
Patients
(5)
Aged
(4)
Immunotherapy
(4)
Lung Neoplasms - Genetics
(4)
Lung Neoplasms - Pathology
(4)
Male
(4)
Mutation
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers

Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices

New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab

Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC

Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study

Optimizing Tissue Use: A Step-wise Approach to Diagnosing Squamous Cell Lung Carcinoma on Small Biopsies

Evaluating of HPV–DNA ISH as an adjunct to p16 testing in oropharyngeal cancer

Pilot Study of Dacomitinib for Patients With Metastatic EGFR -Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib

Optimizing adjuvant therapy in EGFR -mutated non-small cell lung cancer

Tu1913 CHRONIC IMMUNE-RELATED COLITIS IS COMMON AFTER PD-(L)1 TREATMENT AND MAY BE MITIGATED THROUGH EARLY USE OF BIOLOGIC THERAPY

Potential biomarkers for predicting outcomes in CABG cardiothoracic surgeries

COVID-19 in patients with lung cancer

Tu1914 OFFICE-BASED FLEXIBLE SIGMOIDOSCOPY ALLOWS RAPID ASSESSMENT AND MANAGEMENT OF SUSPECTED IMMUNE CHECKPOINT INHIBITOR-RELATED COLITIS

Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study

Corrigendum to “Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer” [Lung Cancer 195 (2024) 107919]

Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline

Optimizing clinical research in a regional cancer center network: A survey-based approach

Therapeutic Effects of Repurposed Therapies in Non‐Small Cell Lung Cancer: What Is Old Is New Again

The utilization of pre-treatment neutrophil to lymphocyte ratio as a predictive marker for response to nivolumab therapy in non small cell lung cancer

Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer

Predictive value of baseline clinicopathological factors in non-small cell lung cancer (NSCLC) patients on checkpoint inhibitors (CPI)

A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer

Outcomes of single-agent PD-(L)-1 versus combination with chemotherapy in patients with PD-L1-high (≥ 50%) lung cancer

A comparison of three clinical factors as predictive markers for response to immunotherapy in non-small cell lung cancer

Suchergebnisse filtern